Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib Maintenance Therapy After alloHCT in AML
NCT07563010Phase 2Not yet recruiting
- Sponsor
- Center for International Blood and Marrow Transplant Research
- Start
- Dec 2026
- Primary completion
- Jun 2031
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Revumenib BID with Placebo BID (2 arms). Primary endpoint: Relapse-Free Survival at 1 year. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07563010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563010.